Found 242 articles for: "basal cell carcinoma"
DNA Repair Enzymes: An Important Role in Skin Cancer Prevention and Reversal of Photodamage‑ A Review of the Literature
March 2015 | Volume 14 | Issue 3 | Original Article | 297 | Copyright © March 2015
The incidence of skin cancer continues to increase annually despite preventative measures. Non-melanoma skin cancer affects more than 1,000,000 people in the United States every year.1 The ...
Read MoreVismodegib as a Neoadjuvant Treatment to Mohs Surgery for Aggressive Basal Cell Carcinoma
March 2015 | Volume 14 | Issue 3 | Original Article | 219 | Copyright © March 2015
BACKGROUND: Vismodegib, a hedgehog pathway inhibitor has been recently introduced as an oral therapy for locally advanced and metastatic basal cell carcinoma. Although treatment of patients with basal...
Read MoreSuccessful Botulinum Toxin (OnabotulinumtoxinA) Treatment of Hailey-Hailey Disease
January 2015 | Volume 14 | Issue 1 | Case Reports | 68 | Copyright © January 2015
Hailey-Hailey disease is a genetic disorder that affects flexural skin with scale, blisters, and maceration. Botulinum toxins have been previously used to treat Hailey-Hailey disease. Here, we present...
Read MoreSystematic Review of Vismodegib Toxicity Profile in the Treatment of Advanced Basal Cell Carcinomas Compared to Other Systemic Therapies in Dermatology
June 2014 | Volume 13 | Issue 6 | Original Article | 729 | Copyright © June 2014
Vismodegib is a first-in-class, hedgehog-signal inhibitor that is FDA-approved for use with advanced basal cell carcinomas (BCCs) that cannot be removed by either surgical resection or treated with ra...
Read MoreProlonged Adverse Events Following Photodynamic Therapy: Regulatory Implications
January 2014 | Volume 13 | Issue 1 | Original Article | 62 | Copyright © January 2014
OBJECTIVE: To determine whether field photodynamic therapy (PDT) of actinic keratoses (AKs) using a novel preparation of 5-aminolevulonic acid (ALA) would result in fewer subsequent invasive skin canc...
Read MoreNonsurgical Treatment Options for Basal Cell Carcinoma - Focus on Advanced Disease
December 2013 | Volume 12 | Issue 12 | Original Article | 1369 | Copyright © December 2013
Basal cell carcinoma (BCC) is the most common cancer in the world. It is typically slow growing and usually effectively managed with surgery. However, BCCs in some patients are unsuitable for surgery...
Read MoreIdentifying Patients at Risk for Recurrent or Advanced BCC
November 2013 | Volume 12 | Issue 11 | Original Article | 1244 | Copyright © November 2013
Basal cell carcinoma (BCC) is a common skin cancer and its incidence is on the rise worldwide. Clinical presentation and histologic examination are used for diagnosis and to stratify BCCs as either l...
Read MoreAdvanced Basal Cell Carcinoma: Therapeutic Options and Considerations for Patient Care
October 2013 | Volume 12 | Issue 10 | Department | 141 | Copyright © October 2013
Vismodegib Ushers in New Era for the Treatment of Basal Cell Carcinoma
Approximately 2.8 million basal cell carcinomas (BCCs) occur in the United States each year, accounting for 80% of a...
Read MoreVismodegib: A Hedgehog Pathway Inhibitor for Locally Advanced and Metastatic Basal Cell Carcinomas
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 154 | Copyright © October 2013
Basal cell carcinomas (BCCs) are the most common cancer in the United States, and the overwhelming majority of BCCs are the result of hedgehog pathway activation. While locally advanced and metastatic...
Read MoreThe Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical, and Psychological Burden of the Disease
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 151 | Copyright © October 2013
The development of vismodegib and its recent approval by the United States Food and Drug Administration for use in patients with locally advanced or metastatic basal cell carcinoma (BCC) carries with ...
Read MoreTreatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 147 | Copyright © October 2013
Historically, basal cell carcinomas (BCCs) that are neither surgically resectable nor candidates for radiation therapy have had few treatment options. The hedgehog pathway inhibitor, vismodegib, repre...
Read MoreIntroduction
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 146 | Copyright © October 2013
Understanding BCC Pathogenesis: Treatment Advancements and Challenges
October 2013 | Volume 12 | Issue 10 | Original Article | 1110 | Copyright © October 2013
Valrubicin Activates PKCα in Keratinocytes: A Conceivable Mode of Action in Treating Hyper-Proliferative Skin Diseases
October 2013 | Volume 12 | Issue 10 | Original Article | 1156 | Copyright © October 2013
BACKGROUND: Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valru...
Read MoreCurcumin: A Novel Treatment for Skin-Related Disorders
October 2013 | Volume 12 | Issue 10 | Original Article | 1131 | Copyright © October 2013
Curcumin, or diferuloylmethane, is a crystalline compound which gives the East Asian spice turmeric its bright yellow color. The medicinal properties of this spice have been referenced in numerous cou...
Read MoreThe Use of Photodynamic Therapy as Chemoprevention for the Treatment of Actinic Keratoses and Reduction in the Number of Non-Melanoma Skin Cancers
October 2013 | Volume 12 | Issue 10 | Editorials | 1085 | Copyright © October 2013
News, Views, and Reviews: Safety & Efficacy of Agents Used for Home Mole Removal and Skin Cancer Treatment in the Internet Age, and Analysis of Cases
September 2013 | Volume 12 | Issue 9 | Features | 1058 | Copyright © September 2013
Recognition of Skin Cancer and Sun Protective Behaviors in Skin of Color
September 2013 | Volume 12 | Issue 9 | Original Article | 1029 | Copyright © September 2013
Sun protective behaviors are not as frequently practiced in skin of color as they are amongst Caucasians.1 Thus providing a reasonable assumption this behavior, or lack thereof, increases the risk of ...
Read MoreCalcium Hydroxylapatite Filler: An Overview of Safety and Tolerability
September 2013 | Volume 12 | Issue 9 | Original Article | 996 | Copyright © September 2013
Soft tissue fillers are becoming increasingly important as nonsurgical treatment options for facial rejuvenation. Calcium hydroxylapatite (CaHA) is an injectable dermal filler that contains uniform Ca...
Read MoreClinical Trial Review
August 2013 | Volume 12 | Issue 8 | Features | 959 | Copyright © August 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read More